Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models
The DOI matches its Crossref record.
Abstract
HM15211 is a novel long-acting GLP-1/GIP/Glucagon triple agonist that is being developed for the treatment of obesity and nonalcoholic fatty liver disease (NASH). Accumulating evidences have shown that obesity, type 2 diabetes, and NASH increase the risk of developing progressive neurodegenerative disease such as Parkinson’s disease (PD) and Alzheimer’s disease (AD). In addition to peripheral contributions, each of incretins consisting HM15211 have neuroprotective effects in several brain diseases like AD, PD, and ischemia. Previously, we demonstrated that HM15211 exerted neuroprotective effects in MPTP induced subacute PD mice model. Here, we evaluated 1) the neuroprotective effects of HM15211 in chronic MPTP/probenecid PD model, and 2) the protection of AD progression in db/db mice. Chronic PD mice model was induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in combination with probenecid injection, twice a week for 5 weeks and HM15211 was administered once a week for 6 weeks. Dopaminergic neuronal death by MPTP/probenecid was protected by HM15211, which was derived from anti-inflammatory and anti-oxidative stress effect by HM15211. Also HM15211 decreased alpha synuclein in striatum of chronic mice PD model. Together with these efficacies, HM15211 significantly improved the MPTP/probenecid induced motor impairments in behavior. A db/db mice are well-established diabetic model and reported that db/db mice develop hyperphosphorylation of tau as they grew older. Thus we chose db/db mice to elucidate the prophylactic effect of HM15211 on AD. After once every 2 days subcutaneous administration for 12 weeks, HM15211 reversed inflammatory cytokines and oxidative stress marker, which were increased in db/db mice. Also, increased phosphorylated tau in db/db mice was decreased by HM15211. Based on these observations, HM15211 might be a potential therapeutic option for the neurodegenerative disease. Disclosure: J.A. Kim: Employee; Self; Hanmi Pharmaceutical. S. Lee: Employee; Self; Hanmi Pharmaceutical. S. Lee: Employee; Self; Hanmi Pharmaceutical. S. Jung: None. Y. Kim: Employee; Self; Hanmi Pharmaceutical. I. Choi: Employee; Self; Hanmi Pharmaceutical. Stock/Shareholder; Self; Hanmi Pharmaceutical. S. Kim: Employee; Self; Hanmi Pharmaceutical. Stock/Shareholder; Self; Hanmi Pharmaceutical.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In mice models, there was a reduction in hyperglycemia, weight loss and increased energy expenditure compared to liraglutide [68,69].”
From The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. (2024) · cites this paper as [68]
Citations
Cites
Still being checked.
Cited by
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Wang, Y., Hu, H., Liu, X., & Guo, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1138499 · Cited by 76
Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 65
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 60
Metadata
- Authors
- KIM, J. A., LEE, S., LEE, S. H., JUNG, S. Y., KIM, Y. H., CHOI, I. Y., & KIM, S. J.
- Affiliations
- Seoul, Korea, Republic of
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-07-01
- Volume
- 67
- Issue
- Supplement_1
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2808743213
- Cited by
- 14
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2020: 2 · 2019: 3 · 2018: 1
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- neuroprotection, Parkinson's disease, Alzheimer's disease, dopaminergic neuron loss, alpha-synuclein, tau hyperphosphorylation, db/db mice, oxidative stress, neuroinflammation, motor impairment, neurodegenerative diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models. https://app.cochat.ai/papers/10.2337/db18-1107-p
- The paper
- KIM, J. A., LEE, S., LEE, S. H., JUNG, S. Y., KIM, Y. H., CHOI, I. Y., & KIM, S. J. (2018). Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models. Diabetes. https://doi.org/10.2337/db18-1107-p
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.